Aegerion Pharmaceuticals Fined $40M for Illegal Marketing of Juxtapid
Filed in: Juxtapid
Filed in: Juxtapid
What is the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program? (2017).Juxtapid, 1-2. doi:http://www.juxtapidremsprogram.com/
Sagonowsky, E. (2017, September 25). Aegerion to pay $35M to settle claims it risked safety with Juxtapid promotions. Retrieved from http://www.fiercepharma.com/legal/aegerion-inks-35m-deal-to-settle-juxtapid-mismarketing-claims